Increasing use of targeted therapies is boosting the cytokine release syndrome management market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Cytokine Release Syndrome Management Market Expected To Reach Based On Its 2026 Value?
The cytokine release syndrome management market size has demonstrated strong growth in recent years. It is projected to expand from $23.76 billion in 2025 to $25.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.5%. This historical expansion can be attributed to several factors, including the increasing adoption of CAR-T therapies, the limited number of CRS treatment options, a reliance on corticosteroids, management primarily within hospital settings, and the elevated mortality risk involved.
The cytokine release syndrome management market size is anticipated to experience substantial growth in the coming years. It is projected to reach $32.35 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period is attributed to the broader application of cell therapies, advancements in immunomodulators, enhanced early detection methods, the establishment of standardized treatment guidelines, and increasing adoption in oncology. Prominent trends expected in this timeframe include the rising use of IL-6 inhibitors, the expansion of CRS management in CAR-T therapy, a heightened focus on early intervention protocols, the growth of intensive care monitoring, and the development of targeted immunomodulators.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Drivers Are Fueling The Growth Of The Cytokine Release Syndrome Management Market?
The growing application of targeted therapies is projected to fuel the expansion of the cytokine release syndrome management market in the future. These therapies refer to medications or medical procedures specifically formulated to impede cancer proliferation and dissemination by disrupting molecular targets implicated in tumor formation. The expanded adoption of targeted therapies stems mainly from their capacity to accurately identify and attack cancer cells, thereby minimizing harm to healthy tissue, boosting the effectiveness of treatment, and lessening adverse reactions in contrast to conventional methods. Effective management of cytokine release syndrome plays a crucial role in optimizing targeted therapies through the regulation of severe inflammatory responses, consequently improving the safety and efficacy of treatments like CAR-T cell therapy and immune checkpoint inhibitors. As an illustration, in January 2024, the American Society of Gene and Cell Therapy, a US-based organization dedicated to gene and cell therapy, reported that the fourth quarter of 2023 saw a 10% increase in gene therapies undergoing Phase III clinical trials. This represented the first such quarterly increase since the third quarter of 2022. Consequently, the expanding utilization of targeted therapies is a key impetus for the development of the cytokine release syndrome management market.
How Are Segments Identified Within The Cytokine Release Syndrome Management Market Segment Framework?
The cytokine release syndrome management market covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies, Corticosteroids, Intravenous Immunoglobulin (IVIG), Targeted Therapy, Supportive Care, Other Treatment Types
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation (HSCT), Autoimmune Diseases, Infections, Other Indications
3) By Route Of Administration: Intravenous (IV), Subcutaneous (SC), Oral, Intramuscular (IM), Intrathecal, Other Routes Of Administration
4) By End Users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Research Institutions, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Tocilizumab, Siltuximab, Infliximab, Rituximab
2) By Corticosteroids: Dexamethasone, Prednisone, Methylprednisolone, Hydrocortisone
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin, Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin, Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin, Polyvalent Intravenous Immunoglobulin
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors, Bruton’s Tyrosine Kinase (BTK) Inhibitors
5) By Supportive Care: Antipyretic Medications, Analgesic Medications, Intravenous Fluids And Electrolyte Solutions, Oxygen Therapy, Vasopressor Agents
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange), Antihistamine Medications, Leukapheresis, Experimental Therapies, Nutritional Support
What Trends Are Influencing The Cytokine Release Syndrome Management Market?
Key players in the cytokine release syndrome management market are concentrating on conducting clinical trials to develop innovative therapies, such as host-directed small molecule drugs, with the goal of modulating the immune response and lessening the severity of cytokine storms without impairing the body’s ability to combat infections or cancer. A host-directed small molecule drug is a low molecular weight compound designed to target the host’s immune signaling pathways to suppress excessive cytokine production, thereby assisting in the management of cytokine release syndrome (CRS) by preventing immune system overactivation. For example, in April 2025, CytoAgents Inc., a US-based biotechnology company, declared the successful completion of the first dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681, a host-directed small molecule drug developed to prevent and treat CRS in patients undergoing CAR T-cell therapy. This investigational therapy showcased a favorable safety profile, with no dose-limiting toxicities or negative impact on CAR T-cell efficacy. The trial, utilizing a rolling six dose-escalation design, is being conducted to assess the safety, tolerability, and preliminary efficacy of CTO1681, along with establishing the recommended phase 2 dose.
Who Are The Companies Competing Within The Cytokine Release Syndrome Management Market?
Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.
Get The Full Cytokine Release Syndrome Management Market Report:
Which Region Leads The Cytokine Release Syndrome Management Market In Terms Of Market Share?
North America was the largest region in the cytokine release syndrome management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cytokine Release Syndrome Management Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Cytokine Release Syndrome Management Market 2026, By The Business Research Company
Release Agents Market Report 2026
https://www.thebusinessresearchcompany.com/report/release-agents-global-market-report
Sustained Release Excipients Market Report 2026
https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report
Leukocyte Adhesion Deficiency Management Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
